The Core Problem

Chestify emerged from an observation that initially appeared surprisingly simple.

While working on a separate venture in 2019, the founding team encountered research suggesting that roughly two-thirds of the global population lacked adequate access to radiology infrastructure.

That insight became the starting point.

The founder’s interpretation of the problem was not that radiologists were absent.

It was that radiological capability itself remained unevenly distributed.

In many parts of Africa, imaging equipment, specialist interpretation, storage systems and reporting workflows remain concentrated in major urban centres.

The consequences compound.

Delayed interpretation delays diagnosis. Delayed diagnosis shifts manageable conditions into more advanced cases.

What became increasingly clear, however, was that radiology itself could not be treated as a standalone software problem.

According to the founder:

Building reliable AI required more than algorithms.

It required imaging workflows, contextual clinical data, secure storage, clinician participation, and infrastructure capable of producing representative African datasets over time.

Chestify therefore evolved beyond image analysis.

Today, the company describes its platform as three connected layers: AI-embedded DICOM Studio supporting image acquisition and clinical workflows, a teleradiology network linking specialists with underserved facilities, and the longer-term ambition of building sovereign radiological data infrastructure capable of supporting both healthcare delivery and future AI development.

That evolution did not appear accidental. It emerged after discovering that software alone could not solve the bottleneck.

---

The Strategic Decision Layer

More interesting than the AI itself was the decision to abandon the assumption that AI alone was enough.

The company initially began with algorithms.

According to the founder, early models were trained using publicly available international datasets.

The results did not hold.

When deployed against local hospital environments, model performance degraded.

That moment appears to have changed the company’s direction.

Instead of continuing to optimise models in isolation, the founders began assembling the surrounding conditions that would allow AI to become clinically useful.

They rebuilt their cloud infrastructure. They developed an AI-embedded DICOM Studio that sits inside the radiology workflow rather than outside it. They created secure biomedical data pipelines and embedded users directly into product development before returning to model optimisation.

The sequencing here is worth examining because many AI companies would normally begin with models and then search for distribution.

Chestify appears to have worked in reverse by building the infrastructure required for trustworthy models to exist in the first place.

That philosophy extends beyond software.

In 2024, the company partnered with one of Ghana’s established medical imaging providers to deploy solar-powered mobile diagnostic units serving underserved communities.

Rather than treating hardware deployment as separate from the software business, the partnership created additional diagnostic capacity while simultaneously strengthening the company’s clinical network and access to representative imaging data.

Another strategic signal is less obvious.

The founder increasingly describes the long-term ambition not as becoming an AI company, but as building Africa’s radiological infrastructure layer.

The AI is one component.

The surrounding system appears to be the larger thesis.

---

Ecosystem Context

What the founding experience reveals about healthcare innovation in Africa is that infrastructure scarcity behaves differently from software scarcity.

One of the strongest observations is not necessarily technological.

Rather, it is geographical.

According to the founder, radiology expertise in Ghana remains heavily concentrated around southern urban centres, creating practical gaps in northern regions.

That imbalance appears to influence both access and diagnosis pathways.

The company described cases where remote interpretation workflows reduced the need for patients to travel long distances for imaging review.

The additional detail shared by the founder reinforces this pattern.

Rather than viewing northern Ghana simply as an underserved market, Chestify increasingly views it as infrastructure opportunity.

The company reports that a significant proportion of its diagnostic activity now originates from northern regions, where specialist distribution remains comparatively limited and demand for imaging services continues to outpace available capacity.

More notable was what happened operationally.

The company’s first resistance did not come from regulators but from clinicians.

Early healthcare professionals interpreted the platform as a potential replacement mechanism rather than an enabling system.

That changed only after Chestify incorporated teleradiology workflows and economic participation for clinicians.

This friction is not unique.

It reflects a recurring condition across professional sectors where automation narratives arrive before incentive alignment.

Another emerging theme concerns governance.

The founder describes a future in which AI companies will increasingly be expected to demonstrate reciprocal value for the communities whose data enables algorithm development.

Chestify’s longer-term vision includes consent-driven biomedical data infrastructure linked to healthcare subsidies and insurance partnerships rather than unrestricted data extraction.

Whether that model becomes commercially viable will be proven in the course of time, but it reflects a growing expectation that AI infrastructure and public benefit will become more tightly connected.

---

Observed Signals

There is strong evidence of long-duration thinking in the founder’s decision-making.

The move from software into infrastructure suggests willingness to absorb slower execution in exchange for deeper positioning.

There is also unusually disciplined evidence of user proximity.

The founder described extended periods embedded inside hospital environments to observe workflows directly rather than infer requirements remotely.

That pattern appears repeatedly throughout the product evolution.

Another notable signal is restraint in capital strategy.

Despite pursuing large infrastructure ambitions, the founder distinguishes between equity financing for software development and debt or revenue-sharing structures for diagnostic infrastructure, suggesting a deliberate effort to avoid unnecessary ownership dilution where predictable operating cash flows may eventually support asset financing.

Equally revealing is the founder’s framework for evaluating investors.

Rather than treating capital as the scarce resource, the public narrative increasingly frames investor selection around what the founder describes as three C’s variables:

Care for the mission,

Capability to contribute beyond funding, and

Connection to opportunities otherwise inaccessible.

Open Variables

The public narrative strongly emphasises infrastructure ownership and radiologist networks.

Less visible at this stage is how the company’s broader infrastructure vision scales operationally across multiple jurisdictions.

The proposed radiological data centres, biomedical insurance integrations and diagnostic campuses introduce additional complexity around financing, sovereign data governance and health system partnerships that will likely differ substantially between countries.

Another important consideration concerns capital intensity.

The founder increasingly positions physical diagnostic infrastructure alongside software as part of Chestify’s long-term strategy.

Whether the combination of revenue-sharing partnerships, debt financing and institutional capital can support that expansion without reducing organisational focus remains an important variable.

These are not contradictions.

Rather, they are the kinds of questions infrastructure companies typically encounter as they transition from software deployment to physical healthcare system.

---

Why This Matters

This case matters because it challenges a common assumption in AI ecosystems.

Many discussions begin with models.

Infrastructure businesses begin elsewhere.

Chestify suggests that, in healthcare, durable advantage may emerge not from developing the most sophisticated algorithms but from building the conditions under which those algorithms remain clinically relevant, locally representative and institutionally trusted.

The company’s evolution also surfaces a broader pattern becoming increasingly visible across African AI ecosystems.

Some of the most ambitious founders are no longer attempting to build software alone.

They are redesigning the physical, operational and governance infrastructure that software depends upon.

For investors, this expands the conversation from AI capability to infrastructure ownership.

For ecosystem operators, it reinforces that meaningful AI ecosystems require far more than model development.

They require data systems, institutional partnerships, trusted workflows and incentives that align technology adoption with public value

---

Final Strategic Takeaway

The strongest infrastructure companies are often not the first to deploy technology. They are the first to realise that technology adoption depends on solving everything around the technology first.

---

This article is drawn from an in-depth founder interview conducted by Afriq IQ with Michael Osei-Gyeabour, Co-founder of Chestify AI Labs. Selected insights and observations are published here.